CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.

ABSTRACT: Targeting cancer cells using chimeric-antigen-receptor (CAR-)T cells has propelled adoptive T-cell therapy (ATT) to the next level. A plentitude of durable complete responses using CD19-specific CAR-T cells in patients suffering from various lymphoid malignancies resulted in the approval by the food and drug administration (FDA) of CD19-directed CAR-T cells for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). A substantial portion of this success in hematological malignancies can be traced back to the beneficial properties of the target antigen CD19, which combines a universal presence on target cells with no detectable expression on indispensable host cells. Hence, to replicate response rates achieved in ALL and DLBCL in the realm of solid tum

SUBMITTER: Harrer DC 

PROVIDER: S-EPMC6928974 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature